Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Duca

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?Margherita Ambrosini, Giovanni Fucà, Matteo Duca, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungFabio Conforti, Chiara Catania, Francesca Toffalorio, et al.
Journal of Thoracic Disease|June 14, 2016
Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancerFrancesco Gelsomino, Maria Rita Castellani, Alfonso Marchianò, et al.
The Breast Journal|February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER studyGabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Tumori|July 9, 2025
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridizationDaniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, et al.
Cancer Reports (Hoboken, N.J.)|November 7, 2025
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the LiteratureSimone Rota, Carolina Sciortino, Silvia Damian, et al.
Scientific Reports|February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockadeLicia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Molecular Cancer Therapeutics|February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid TumorsMatteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
Tumori|April 27, 2024
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trialsLuca Agnelli, Andrea Villa, Fouziah Butt, et al.
Exploration of Targeted Anti-Tumor Therapy|November 7, 2022
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samplesIolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?Margherita Ambrosini, Giovanni Fucà, Matteo Duca, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungFabio Conforti, Chiara Catania, Francesca Toffalorio, et al.
Journal of Thoracic Disease|June 14, 2016
Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancerFrancesco Gelsomino, Maria Rita Castellani, Alfonso Marchianò, et al.
The Breast Journal|February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER studyGabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Tumori|July 9, 2025
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridizationDaniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, et al.
Cancer Reports (Hoboken, N.J.)|November 7, 2025
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the LiteratureSimone Rota, Carolina Sciortino, Silvia Damian, et al.
Scientific Reports|February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockadeLicia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Molecular Cancer Therapeutics|February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid TumorsMatteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
Tumori|April 27, 2024
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trialsLuca Agnelli, Andrea Villa, Fouziah Butt, et al.
Exploration of Targeted Anti-Tumor Therapy|November 7, 2022
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samplesIolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, et al.
Pageof 4